Literature DB >> 16150935

Dysfunctional T regulatory cells in multiple myeloma.

Rao H Prabhala1, Paola Neri, Jooeun E Bae, Pierfrancesco Tassone, Masood A Shammas, Charles K Allam, John F Daley, Dharminder Chauhan, Elizabeth Blanchard, Hemant S Thatte, Kenneth C Anderson, Nikhil C Munshi.   

Abstract

Multiple myeloma (MM) is characterized by the production of monoclonal immunoglobulin and is associated with suppressed uninvolved immunoglobulins and dysfunctional T-cell responses. The biologic basis of this dysfunction remains ill defined. Because T regulatory (T(reg)) cells play an important role in suppressing normal immune responses, we evaluated the potential role of T(reg) cells in immune dysfunction in MM. We observed a significant increase in CD4+ CD25+ T cells in patients with monoclonal gammopathy of undetermined significance (MGUS) and in patients with MM compared with healthy donors (25% and 26%, respectively, vs 14%); however, T(reg) cells as measured by FOXP3 expression are significantly decreased in patients with MGUS and MM compared with healthy donors. Moreover, even when they are added in higher proportions, T(reg) cells in patients with MM and MGUS are unable to suppress anti-CD3-mediated T-cell proliferation. This decreased number and function of T(reg) cells in MGUS and in MM may account, at least in part, for the nonspecific increase in CD4+ CD25+ T cells, thereby contributing to dysfunctional T-cell responses.

Entities:  

Mesh:

Year:  2005        PMID: 16150935      PMCID: PMC1895365          DOI: 10.1182/blood-2005-08-3101

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  29 in total

Review 1.  Natural versus adaptive regulatory T cells.

Authors:  Jeffrey A Bluestone; Abul K Abbas
Journal:  Nat Rev Immunol       Date:  2003-03       Impact factor: 53.106

2.  Control of regulatory T cell development by the transcription factor Foxp3.

Authors:  Shohei Hori; Takashi Nomura; Shimon Sakaguchi
Journal:  Science       Date:  2003-01-09       Impact factor: 47.728

3.  Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.

Authors:  Richard LeBlanc; Teru Hideshima; Laurence P Catley; Reshma Shringarpure; Renate Burger; Nicholas Mitsiades; Constantine Mitsiades; Puneet Cheema; Dharminder Chauhan; Paul G Richardson; Kenneth C Anderson; Nikhil C Munshi
Journal:  Blood       Date:  2003-09-25       Impact factor: 22.113

4.  Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.

Authors:  Fumiko Ichihara; Koji Kono; Akihiro Takahashi; Hiromichi Kawaida; Hidemitsu Sugai; Hideki Fujii
Journal:  Clin Cancer Res       Date:  2003-10-01       Impact factor: 12.531

5.  Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.

Authors:  Manuelle Viguier; Fabrice Lemaître; Olivier Verola; Min-Sun Cho; Guy Gorochov; Louis Dubertret; Hervé Bachelez; Philippe Kourilsky; Laurent Ferradini
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

6.  CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.

Authors:  François Ghiringhelli; Nicolas Larmonier; Elise Schmitt; Arnaud Parcellier; Dominique Cathelin; Carmen Garrido; Bruno Chauffert; Eric Solary; Bernard Bonnotte; François Martin
Journal:  Eur J Immunol       Date:  2004-02       Impact factor: 5.532

Review 7.  Advances in biology of multiple myeloma: clinical applications.

Authors:  Teru Hideshima; P Leif Bergsagel; W Michael Kuehl; Kenneth C Anderson
Journal:  Blood       Date:  2004-04-15       Impact factor: 22.113

8.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma.

Authors:  Neil A Marshall; Linsey E Christie; Laura R Munro; Dominic J Culligan; Peter W Johnston; Robert N Barker; Mark A Vickers
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

9.  Suppressor T cells in human diseases.

Authors:  Clare Baecher-Allan; David A Hafler
Journal:  J Exp Med       Date:  2004-07-26       Impact factor: 14.307

10.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

Authors:  J H Kehrl; L M Wakefield; A B Roberts; S Jakowlew; M Alvarez-Mon; R Derynck; M B Sporn; A S Fauci
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

View more
  88 in total

1.  Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry.

Authors:  Roberto J Pessoa de Magalhães; María-Belén Vidriales; Bruno Paiva; Carlos Fernandez-Gimenez; Ramón García-Sanz; Maria-Victoria Mateos; Norma C Gutierrez; Quentin Lecrevisse; Juan F Blanco; Jose Hernández; Natalia de las Heras; Joaquin Martinez-Lopez; Monica Roig; Elaine Sobral Costa; Enrique M Ocio; Martin Perez-Andres; Angelo Maiolino; Marcio Nucci; Javier De La Rubia; Juan-Jose Lahuerta; Jesús F San-Miguel; Alberto Orfao
Journal:  Haematologica       Date:  2012-07-06       Impact factor: 9.941

Review 2.  Immunotherapy strategies for multiple myeloma: the present and the future.

Authors:  Frederick L Locke; Taiga Nishihori; Melissa Alsina; Mohamed A Kharfan-Dabaja
Journal:  Immunotherapy       Date:  2013-09       Impact factor: 4.196

Review 3.  The bone marrow stroma in hematological neoplasms--a guilty bystander.

Authors:  Claudio Tripodo; Sabina Sangaletti; Pier P Piccaluga; Sonam Prakash; Giovanni Franco; Ivan Borrello; Attilio Orazi; Mario P Colombo; Stefano A Pileri
Journal:  Nat Rev Clin Oncol       Date:  2011-03-29       Impact factor: 66.675

Review 4.  Immune therapies.

Authors:  Rao H Prabhala; Nikhil C Munshi
Journal:  Hematol Oncol Clin North Am       Date:  2007-12       Impact factor: 3.722

5.  Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.

Authors:  Güllü Topal Görgün; Gregory Whitehill; Jennifer L Anderson; Teru Hideshima; Craig Maguire; Jacob Laubach; Noopur Raje; Nikhil C Munshi; Paul G Richardson; Kenneth C Anderson
Journal:  Blood       Date:  2013-01-15       Impact factor: 22.113

6.  Blocking IFNAR1 inhibits multiple myeloma-driven Treg expansion and immunosuppression.

Authors:  Yawara Kawano; Oksana Zavidij; Jihye Park; Michele Moschetta; Katsutoshi Kokubun; Tarek H Mouhieddine; Salomon Manier; Yuji Mishima; Naoka Murakami; Mark Bustoros; Romanos Sklavenitis Pistofidis; Mairead Reidy; Yu J Shen; Mahshid Rahmat; Pavlo Lukyanchykov; Esilida Sula Karreci; Shokichi Tsukamoto; Jiantao Shi; Satoshi Takagi; Daisy Huynh; Antonio Sacco; Yu-Tzu Tai; Marta Chesi; P Leif Bergsagel; Aldo M Roccaro; Jamil Azzi; Irene M Ghobrial
Journal:  J Clin Invest       Date:  2018-05-14       Impact factor: 14.808

Review 7.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 8.  Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Authors:  H Quach; D Ritchie; A K Stewart; P Neeson; S Harrison; M J Smyth; H M Prince
Journal:  Leukemia       Date:  2009-11-12       Impact factor: 11.528

9.  MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma.

Authors:  Masahisa Jinushi; Matthew Vanneman; Nikhil C Munshi; Yu-Tzu Tai; Rao H Prabhala; Jerome Ritz; Donna Neuberg; Kenneth C Anderson; Daniel Ruben Carrasco; Glenn Dranoff
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-17       Impact factor: 11.205

10.  The role of regulatory T cells in cancer.

Authors:  Tai-You Ha
Journal:  Immune Netw       Date:  2009-12-31       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.